| Drug General Information |
| Drug ID |
D07MJD
|
| Former ID |
DNC009956
|
| Drug Name |
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C20H16O4S
|
| Canonical SMILES |
C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3CC(=O)O
|
| InChI |
1S/C20H16O4S/c21-20(22)14-17-8-4-5-9-19(17)25(23,24)18-12-10-16(11-13-18)15-6-2-1-3-7-15/h1-13H,14H2,(H,21,22)
|
| InChIKey |
HGICQEUHJFERNR-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
MMP-9 |
Target Info |
Inhibitor |
[1]
|
|---|
| 72 kDa type IV collagenase |
Target Info |
Inhibitor |
[1]
|
| Neutrophil collagenase |
Target Info |
Inhibitor |
[1]
|
| Collagenase 3 |
Target Info |
Inhibitor |
[1]
|
| MMP-12 |
Target Info |
Inhibitor |
[1]
|
| Matrix metalloproteinase-14 |
Target Info |
Inhibitor |
[1]
|
| Matrixmetalloproteinase |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
TNF signaling pathway
|
|
Leukocyte transendothelial migration
|
|
Estrogen signaling pathway
|
|
Hepatitis B
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Bladder cancerhsa04670:Leukocyte transendothelial migration
|
|
GnRH signaling pathway
|
|
Bladder cancerhsa04668:TNF signaling pathway
|
|
NetPath Pathway
|
ID Signaling Pathway
|
|
TWEAK Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
TNFalpha Signaling PathwayNetPath_22:Leptin Signaling Pathway
|
|
TCR Signaling Pathway
|
|
ID Signaling PathwayNetPath_13:IL1 Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
|
IL5 Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-presenilin pathway
|
|
Plasminogen activating cascade
|
|
CCKR signaling map STP00004:Alzheimer disease-presenilin pathwayP00004:Alzheimer disease-presenilin pathwayP00004:Alzheimer disease-presenilin pathway
|
|
Plasminogen activating cascadeP00004:Alzheimer disease-presenilin pathway
|
|
Pathway Interaction Database
|
LPA receptor mediated events
|
|
Plasma membrane estrogen receptor signaling
|
|
Osteopontin-mediated events
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Validated targets of C-MYC transcriptional activation
|
|
CXCR4-mediated signaling events
|
|
amb2 Integrin signaling
|
|
Syndecan-4-mediated signaling events
|
|
AP-1 transcription factor network
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
Syndecan-1-mediated signaling events
|
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
FGF signaling pathwaylysophospholipid_pathway:LPA receptor mediated events
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Direct p53 effectors
|
|
ATF-2 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Syndecan-2-mediated signaling eventsupa_upar_pathway:Urokinase-type plasminogen activator (uPA) and uPAR-mediated signalingupa_upar_pathway:Urokinase-type plasminogen activator (uPA) and uPAR-mediated signalinghif2pathway:HIF-2-alpha transcription factor network
|
|
Signaling events mediated by focal adhesion kinase
|
|
Reactome
|
Collagen degradation
|
|
Degradation of the extracellular matrix
|
|
Activation of Matrix Metalloproteinases
|
|
Assembly of collagen fibrils and other multimeric structures
|
|
EPH-ephrin mediated repulsion of cellsR-HSA-1442490:Collagen degradation
|
|
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
|
Activation of Matrix MetalloproteinasesR-HSA-1442490:Collagen degradation
|
|
Assembly of collagen fibrils and other multimeric structuresR-HSA-1442490:Collagen degradation
|
|
Degradation of the extracellular matrixR-HSA-1442490:Collagen degradation
|
|
WikiPathways
|
Endochondral Ossification
|
|
IL1 and megakaryotyces in obesity
|
|
Mammary gland development pathway - Involution (Stage 4 of 4)
|
|
Activation of Matrix Metalloproteinases
|
|
Degradation of collagen
|
|
Spinal Cord Injury
|
|
AGE/RAGE pathway
|
|
TWEAK Signaling Pathway
|
|
Angiogenesis
|
|
Osteopontin Signaling
|
|
Matrix MetalloproteinasesWP2769:Activation of Matrix Metalloproteinases
|
|
Matrix MetalloproteinasesWP474:Endochondral Ossification
|
|
Oncostatin M Signaling Pathway
|
|
Matrix MetalloproteinasesWP366:TGF beta Signaling Pathway
|
|
Matrix MetalloproteinasesWP615:Senescence and Autophagy in Cancer
|
|
Matrix Metalloproteinases
|
| References |
| REF 1 | J Med Chem. 2009 Oct 22;52(20):6347-61.Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors. |
|---|
